| ⚠ Research Use Only (RUO). This compound is supplied exclusively for laboratory and preclinical research by qualified institutions. It is not for human or animal use, not intended to diagnose, treat, cure, or prevent any disease, and is not FDA-approved. Sale is restricted to verified research and institutional accounts. |
Researchers studying growth hormone secretion often work with CJC-1295 and Ipamorelin together because the two peptides act on separate receptor systems in the pituitary. This guide covers the mechanism of each compound, why the combination is used in GH-pathway research, the relevant published literature, and how Hotspan verifies compound identity and purity for research customers.
What Is CJC-1295?
CJC-1295 (Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) — a 29-amino-acid sequence with four substitutions (positions 2, 8, 15, and 27) that increase GHRH-receptor binding and resistance to enzymatic degradation.
In pituitary tissue models, CJC-1295 binds GHRH receptors on somatotroph cells, stimulating GH synthesis and release in a sustained, pulsatile pattern. Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) reported dose-dependent GH and IGF-1 elevations persisting up to 28 days in a clinical trial population, with no serious adverse events recorded.
No DAC vs. DAC: The No DAC form lacks the Drug Affinity Complex — a lysine modification that binds albumin and extends half-life to roughly 6–8 days. No DAC produces a shorter, more physiologic pulse and is the form typically used in pulsatility research; DAC-modified CJC-1295 is used where sustained baseline elevation is the research variable of interest.
What Is Ipamorelin?
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective growth hormone secretagogue, mimicking ghrelin at the GHS-R1a receptor.
Unlike many other GHRPs, Ipamorelin does not meaningfully elevate cortisol, prolactin, ACTH, FSH, LH, or TSH in study models — a selectivity profile that made it a useful research tool for isolating GH-specific effects. Raun et al. (European Journal of Endocrinology, 1998) characterized Ipamorelin as the first selective GH secretagogue of its kind, confirming GH-specific release without broader pituitary activation.
Why Researchers Study the Combination
CJC-1295 and Ipamorelin engage two distinct intracellular signaling cascades:
| Peptide | Receptor Target | Mechanism | Studied Effect |
| CJC-1295 (No DAC) | GHRH Receptor | Gs → cAMP → PKA → GH gene transcription | GH pulse amplitude |
| Ipamorelin | GHS-R1a (ghrelin receptor) | Gq → intracellular Ca²⁺ → PKC | GH pulse frequency |
Because these pathways are independent, co-administration in study models has been associated with a substantially larger combined GH output than either compound alone, with Ipamorelin producing an early peak within roughly two hours and CJC-1295 extending elevated output over a longer window. This dual-pathway kinetic is a common reason researchers select the pairing for GH pulsatility study designs.
Current Research Applications
Published and ongoing research involving this pathway combination includes:
- GH pulsatility modeling — dual-receptor activation as a tool for studying endogenous GH rhythm
- Body composition research — lean mass and fat oxidation dynamics in GH-deficient models
- Bone metabolism — Ipamorelin’s effect on longitudinal bone growth in rodent models (Johansen et al., 1999)
- Tissue repair pathways — downstream IGF-1 elevation and protein synthesis signaling
- Sleep architecture — correlation between GH secretion and slow-wave sleep
- Connective tissue signaling — GH-driven collagen synthesis models
- Metabolic signaling — lipolysis and glucose uptake regulation under elevated GH
- Neural IGF-1 receptor activity — a growing area of cognitive-research interest
Purity and Formulation Standards
Hotspan’s research-grade CJC-1295/Ipamorelin blend ships lyophilized in a 1:1 ratio (5 mg CJC-1295 No DAC : 5 mg Ipamorelin, 10 mg total per vial), meeting the following minimum specifications:
- HPLC purity: ≥98%, confirmed per peptide (not blended average)
- Mass spectrometry: molecular weight confirmation for both compounds
- Endotoxin testing: ≤1 EU/mg
- Batch-specific Certificate of Analysis from an independent third-party laboratory, with a batch number matching the vial label.
CJC-1295 for Growth Hormone Boost
We recommend researchers request and retain the batch-matched COA for every lot before use in any protocol, and decline any vendor offering a generic or undated certificate.
Storage (Unopened, Lyophilized)
Store unopened vials at –20°C, protected from light and humidity. Properly stored, shelf life is approximately 24 months. Reconstitution methodology, handling of prepared solutions, and in-protocol storage parameters should follow your institution’s own laboratory SOPs; Hotspan does not provide individualized preparation instructions on this page, as reconstitution and administration protocols are determined by the researcher’s institutional and IACUC/IRB-governed procedures.
Sourcing
Hotspan supplies research-grade CJC-1295/Ipamorelin blend to verified research and institutional accounts, with third-party batch-matched COAs on every lot and HPLC purity confirmation prior to shipment.
| Vial Size | Contents | Price |
| 10 mg | CJC-1295 No DAC / Ipamorelin (5 mg : 5 mg) | $79 |
Request research access → hotspan.com/product/cjc-1295-ipamorelin/
Interested in physician-guided longevity protocols? Hotspan also offers prescription-based programs supervised by licensed physicians through our clinical network. Learn more → hotspan.com
Frequently Asked Questions
What is the CJC-1295/Ipamorelin blend used for in research?
It’s used to study dual-pathway GH activation — GHRH receptor signaling (CJC-1295) and ghrelin receptor signaling (Ipamorelin) within a single research protocol.
Does Ipamorelin raise cortisol in research models?
Published data indicates it selectively stimulates GH release without significantly affecting cortisol, ACTH, prolactin, or other pituitary hormones, distinguishing it from other compounds in its class.
What’s the difference between CJC-1295 with DAC and without DAC?
DAC-modified CJC-1295 binds albumin and extends half-life to 6–8 days for sustained elevation studies; No DAC has a shorter half-life suited to pulsatility research.
What purity standard applies to this blend?
≥98% HPLC purity per component, mass spectrometry confirmation, and a batch-matched third-party COA.
Is this product FDA-approved?
No. Both peptides are non-FDA-approved research compounds supplied strictly for laboratory and institutional research use.
Who can purchase this product?
Licensed researchers, academic institutions, and laboratory professionals conducting in vitro or preclinical research. This product is not sold for personal or human use.
Conclusion
The CJC-1295/Ipamorelin combination gives researchers a way to study two independent GH-secretion pathways in a single model — GHRH receptor signaling through CJC-1295 and ghrelin receptor signaling through Ipamorelin. At Hotspan, every batch is third-party verified and COA-matched before it ships, because sourcing integrity is foundational to research you can trust.